Corcept Therapeutics Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| CORT | LLY | |
|---|---|---|
| Market Cap | $12.13 billion | $1.09 trillion |
| Revenue (TTM) | $741.17 million | — |
| Net Income (TTM) | $106.11 million | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| CORT | LLY | |
|---|---|---|
| P/E Ratio | 131.57 | — |
| Price / Book | 19.19 | — |
| Price / Sales | 16.36 | — |
CORT and LLY split the valuation factors evenly.
Profitability
| CORT | LLY | |
|---|---|---|
| Net Margin | 14.32% | — |
| Return on Equity | 16.79% | — |
CORT and LLY split the profitability factors evenly.
Risk & Sentiment
| CORT | LLY | |
|---|---|---|
| Short Interest | 16.06% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: CORT overview, CORT financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.